CoChat

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Open access
Prendecki, Maria, Clarke, Candice, Edwards, Helena, McIntyre, Stacey, Mortimer, Paige, Gleeson, Sarah, Martin, Paul, Thomson, Tina, Randell, Paul, Shah, Anand, Singanayagam, Aran, Lightstone, Liz, Cox, Alison, Kelleher, Peter, Willicombe, Michelle, McAdoo, Stephen P · 2021 · Annals of the Rheumatic Diseases
Cited by 243

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination. METHODS: Serological and T-cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140 participants receiving immunosuppression for autoimmune rheumatic and glomerular diseases. RESULTS: Following first-dose vaccine, 28.6% (34/119) of infection-naïve participants seroconverted and 26.0% (13/50) had detectable T-cell responses to SARS-CoV-2. Immune responses were augmented by second-dose vaccine, increasing seroconversion and T-cell response rates to 59.3% (54/91) and 82.6% (38/46), respectively. B-cell depletion at the time of vaccination was associated with failure to seroconvert, and tacrolimus therapy was associated with diminished T-cell responses. Reassuringly, only 8.7% of infection-naïve patients had neither antibody nor T-cell responses detected following second-dose vaccine. In patients with evidence of prior SARS-CoV-2 infection (19/140), all mounted high-titre antibody responses after first-dose vaccine, regardless of immunosuppressive therapy. CONCLUSION: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, when assessed by a combination of serology and cell-based assays, although the response is impaired compared with healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. We suggest that repeat vaccine doses for serological non-responders should be investigated as means to induce more robust immunological response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2021-220626

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 243

Metadata

Authors
Prendecki, M., Clarke, C., Edwards, H., McIntyre, S., Mortimer, P., Gleeson, S., Martin, P., Thomson, T., Randell, P., Shah, A., Singanayagam, A., Lightstone, L., Cox, A., Kelleher, P., Willicombe, M., & McAdoo, S. P.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2021-10
Volume
80
Issue
10
Pages
1322-1329
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3190398149
Cited by
243
References
14
FWCI
15.92
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. https://app.cochat.ai/papers/10.1136/annrheumdis-2021-220626
The paper
Prendecki, M., Clarke, C., Edwards, H., McIntyre, S., Mortimer, P., Gleeson, S., Martin, P., Thomson, T., Randell, P., Shah, A., Singanayagam, A., Lightstone, L., Cox, A., Kelleher, P., Willicombe, M., & McAdoo, S. P. (2021). Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-220626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.